anti-trans-N,N',C-triphenylformazan | 25129-56-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: anti-trans-N,N',C-triphenylformazan
• 英文别名: 1,3,5-triphenylformazan；(1E,3E)-1,3,5-Triphenyl-formazan
• CAS: 25129-56-0
• 化学式: C₁₉H₁₆N₄
• 分子量: 300.363
• InChiKey: BEIHVSJTPTXQGB-FACDVXMNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.24
• 重原子数：
  23.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.11
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  anti-trans-N,N',C-triphenylformazan 在 氯 作用下， 以 乙醚 、 乙醇 为溶剂， 以75%的产率得到2,3,5-triphenyl-tetrazolium chloride
  参考文献：
  名称：

  Method for preparing 2H-tetrazolium chloride and 2H-tetrazolium chloride

  摘要：

  一种制备具有一般式##STR1## 的2H-四唑氯化物盐的方法，其中R.sub.1和R.sub.2为H、OH、NO.sub.2、Cl或OCH.sub.2 COOH，n为0到3，并且还包括具有式##STR2## 的二2H-四唑氯化物盐，其中相应的福尔马赞在极性有机溶剂介质中在-5℃至+20℃的温度下被氯氧化。

  公开号：

  US04143049A1

文献信息

• An aqueous thermally bleachable composition useful in a photothermographic element
  申请人：EASTMAN KODAK COMPANY

  公开号：EP1217431A2

  公开（公告）日：2002-06-26

  This invention relates to a photothermographic element comprising a support, at least one photothermographic image-receiving layer, and at least one antihalation layer or a filter layer, wherein the antihalation or filer layer comprises an aqueous heat-bleachable composition comprising at least one dye and at least one hexaarylbiimidazole in the form of particles dispersed in a matrix comprising a hydrophilic or aqueous dispersible polymer.

  本发明涉及一种光热成像元件，该元件包括一个支架、至少一个光热成像图像接收层和至少一个防光晕层或过滤层，其中防光晕层或过滤层包括一种水性热漂白组合物，该组合物包括至少一种染料和至少一种六芳基咪唑，该染料和六芳基咪唑以颗粒的形式分散在由亲水性或水分散性聚合物组成的基质中。
• CYTOPROTECTIVE AGENT
  申请人：National University Corporation Tokyo University Of Agriculture and Technology

  公开号：EP2452679A1

  公开（公告）日：2012-05-16

  Disclosed is a cytoprotective agent for use with respect to ischemic damage, including as an active ingredient a triprenyl phenol compound represented by the following general formula (I), wherein X is -CHY-C(CH3)2Z, Y and Z are each independently -H or -OH, or jointly form a single bond, and R represents a hydrogen atom or a substituent with a molecular weight of 1000 or less.

  公开了一种用于缺血性损伤的细胞保护剂，包括作为活性成分的由以下通式（I）代表的三烯丙基酚化合物，其中 X 为-CHY-C(CH3)2Z，Y 和 Z 各自独立地为-H 或-OH，或共同形成单键，R 代表氢原子或分子量为 1000 或以下的取代基。
• Therapeutic use of mitochondria and combined mitochondrial agent
  申请人：Children's Medical Center Corporation

  公开号：US10370458B2

  公开（公告）日：2019-08-06

  The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

  本公开涉及包含分离线粒体或联合线粒体制剂的组合物，以及使用此类组合物治疗疾病的方法。
• Methods and compositions of bile acids and salts for reduction of fat
  申请人：MEDYTOX INC.

  公开号：US10729700B2

  公开（公告）日：2020-08-04

  The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof.

  本发明涉及治疗受试者脂肪沉积物堆积的组合物和方法。本发明提供了一种减少脂肪沉积的非手术方法，包括向有需要的受试者施用有效量的药学上可接受的制剂中的一种或多种胆酸盐和去氧胆酸盐的溶脂浓度。
• GSNO reductase inhibitor as an adjunct therapy with remote ischemic conditioning and thrombolytic reperfusion therapies in cerebral thrombosis and/or thromboembolic stroke
  申请人：KING ABDULAZIZ UNIVERSITY

  公开号：US11071733B1

  公开（公告）日：2021-07-27

  Stroke patients with comorbidities, such as diabetes, hypertension, or other conditions associated with cardiovascular, pulmonary or renal disease do not respond well to current treatments for stroke. An inhibitor of S-nitrosoglutathione reductase (GSNOR) is administered as an adjunct therapy with remote ischemic conditioning (RIC) to treat a stroke in a subject having at least one comorbidity, such as diabetes and hypertension. When performed in conjunction with GRI therapy and RIC, intravenous tissue plasminogen activator therapy (IVT) for thrombolysis and/or endovascular thrombectomy (EVT) for clot retrieval are effective in subjects with comorbidities, even after five hours post-onset of stroke.

  患有合并症（如糖尿病、高血压或其他与心血管、肺部或肾脏疾病相关的病症）的中风患者对目前治疗中风的方法反应不佳。一种 S-亚硝基谷胱甘肽还原酶抑制剂（GSNOR）可作为远程缺血调理（RIC）的辅助疗法，用于治疗至少患有一种合并症（如糖尿病和高血压）的中风患者。在结合 GRI 治疗和 RIC 的情况下，静脉注射组织纤溶酶原激活剂疗法（IVT）进行溶栓和/或血管内血栓切除术（EVT）进行血栓清除，对有合并症的受试者是有效的，即使是在中风发生后 5 小时之后。